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Summary
Members of the European Society for Immunodeficiencies (ESID) and other
colleagues have updated themulti-stage expert-opinion-based diagnostic pro-
tocol for non-immunologists incorporating newly defined primary immuno-
deficiency diseases (PIDs). The protocol presented here aims to increase the
awareness of PIDs among doctors working in different fields. Prompt identi-
fication of PID is important for prognosis, but this may not be an easy task.
The protocol therefore starts from the clinical presentation of the patient.
Because PIDs may present at all ages, this protocol is aimed at both adult and
paediatric physicians. The multi-stage design allows cost-effective screening
for PID of the large number of potential cases in the early phases, with more
expensive tests reserved for definitive classification in collaboration with a
specialist in the field of immunodeficiency at a later stage.
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Introduction
In 2006, the Clinical Working Party of the European Society
for Immunodeficiencies (ESID) published a multi-stage
diagnostic protocol suitable for all doctors [1]. The protocol
started from the clinical presentation of both paediatric and
adult patients. Many primary immunodeficiency diseases
(PIDs) present in childhood, but the most common clini-
cally significant PID, ‘common variable immunodeficiency
disorders’ (CVID), has a peak onset in the second and third
decades of life. The multi-stage design allowed timely iden-
tification of potential PID by all doctors, while more costly
elaborate tests were reserved for definitive classification at a
later stage, in collaboration with an immunologist special-
ized in the field of immunodeficiency and a specialized
laboratory.
Since 2006, many new PIDs have been identified; the
International Union of Immunological Societies (IUIS)
Expert Committee on Primary Immunodeficiencies pub-
lished updates of their classification of PIDs, the latest in
2009 [2]. We have therefore updated the 2006 diagnostic
protocol, using the IUIS 2009 paper and its references as the
basis for clinical disease entities of PIDs. Additionally, a
PubMed search was performed from 2007 onwards; several
papers discussing the recognition of potential PID in every-
day practice were found [3–13], and all were basedmainly on
expert opinion. All ESID members received an invitation to
participate in this effort. [Searchstrategy, papers selected for
algorithms designed for identification of potential PID
patients in everyday clinical practice published in English in
international papers: 1. ‘Related citations’ for the original
paper [1] (three relevant hits, references [3–5]); ‘Immuno-
logic Deficiency Syndromes/*classification[MeSH] NOT
HIV NOT AIDS NOT HTLV NOT Simian’ (no additional
relevant hits); ‘Immunologic Deficiency Syndromes/
*diagnosis[MeSH] NOT HIV NOT AIDS NOT HTLV NOT
Simian’ (eight additional relevant hits, including the original
ESID paper, references [1,4,6–11]); two additional papers
suggested by contributors (references [12,13]).]
While the general outline of the diagnostic protocol has
remained the same, novel PIDs have been incorporated. The
body of knowledge concerning PIDs has expanded consid-
erably; therefore, possible diagnoses are now presented
separately from the clinical protocols. Because evidence
supporting diagnostic decisions is still limited, the protocols
are based largely on consensus of expert opinions.
Do not forget PID and pick up the signs; it is
life-saving
Considering the possibility of a PID is the key to the
diagnosis. Unfortunately, the awareness of PIDs among
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professionals is low, as PIDs are considered rare and complex
diseases. However, the incidence of PIDs ranges – depending
on the disease – from 1:500 for often asymptomatic immu-
noglobulin (Ig)A deficiency to 1:500 000 [14,15]; all PIDs
taken together may be as frequent as 1:2000 [16]. Like any
other diagnostic process, symptoms from the history
(Table 1a), signs on physical examination (Table 1b) and
baseline blood tests (Table 1c) should alert any physician
to the possibility of PID in children and adults, even
though they are unfamiliar with the precise possible
diagnosis.
This is important, as successful treatment of a child with
severe PID such as severe combined immunodeficiency
(SCID) is dependent upon rapid recognition [17]. Non-
immunologists such as general paediatricians play a vital
role. Leucocyte differential and immunoglobulin isotype
levels enable detection in most cases; these can be per-
formed in many hospitals. Less urgent, but still important if
future organ damage and decreased quality of life and life-
span are to be prevented, is the timely recognition of late-
onset as well as less pronounced forms of PID in older
children and adults [18]. Non-immunologists such as
primary care physicians, general paediatricians, pulmonolo-
gists and ear, nose and throat (ENT) specialists play an
important role here. Common examples are antibody
deficiencies such as CVID and specific anti-polysaccharide
antibody deficiency (SPAD) [19,20]. These generally present
with recurrent respiratory infections, by far the most
common clinical presentation of PID. Confusingly, this
clinical presentation is often encountered in everyday prac-
tice, especially in young children, but also in older children
and adults in any pulmonology or ENT service. Most of
these patients do not have PID. However, when more than
one pneumonia occurs, bronchiectasis is present, the infec-
tions fail to clear with conventional treatment or continue
to occur when a young child grows older, immunological
investigations are needed, and consultation of an immu-
nologist is highly recommended.
Family history is a vital clue to the diagnosis of PID, as
although patients with recurrent infections do not often have
PID, this becomes much more likely when it ‘runs in the
family’. This also holds true for adult patients who can
present with late-onset forms of disease.
Pattern recognition is the key to identification
PIDs tend to present in one of eight different clinical presen-
tations (Table 2, column 1), determined by the underlying
pathology of the disease (Table 3). Either initially or during
follow-up some patients may show features of more than
one clinical presentation, which can be confusing. Encoun-
tered pathogens (Table 2, column 2) can help to clarify the
pattern, because specific immunological defects will lead to
particular patterns of infection [21]. Associated features
(Table 2, column 3) and age of presentation can also help.
Most PIDs present in childhood but due to, for example,
hypomorphic mutation, typical paediatric disease may
present later [22]. CVID is themost common PID presenting
in adulthood [5].
In column 5 of Table 2, directions towards the appropri-
ate multi-stage diagnostic protocol for suspected immuno-
deficiency (Figs 1–3; Tables 4 and 5) are given, using the
clinical presentation as the starting-point. In the protocols,
severe defects are ruled out first with widely available
screening tests (step 1; Figs 1–3). Less severe forms of PID
can be diagnosed later (steps 2–4; Figs 1–3), after more fre-
quent non-immunological diseases have been ruled out
(Table 2, column 4). It is essential to use age-matched ref-
erence values [23–25] to avoid misinterpreting test results,
especially in young infants who normally have a relative
lymphocytosis and a high level of maternal immunoglobu-
lins in their blood. Beyond the first step of each protocol,
and in all cases where a severe PID such as SCID is sus-
pected, timely collaboration with an immunologist to
decide on further diagnostic steps and to aid with the inter-
pretation of the results is highly recommended.
Secondary immunodeficiencies present in a similar
fashion to PIDs. Human immunodeficiency virus (HIV)
infection occurs much more frequently in some parts of the
world. Also, drugs, malignancies and diseases which cause
protein and/or lymphocyte loss may cause secondary immu-
nodeficiency; this is more common than unrecognized PID
in adults [5]. It is important to eliminate these possibilities
before making a definitive diagnosis of PID.
Many new PIDs have been identified in the past decades,
and more are likely in the near future, so this multi-stage
diagnostic protocol will need to be revised from time to
time.
Take-home messages
• The key to detect a PID is to consider the possibility.
• PIDs almost always present with one or more of eight
clinical presentations; these can be used as the starting-
point to enter the appropriate diagnostic protocol.
• SCID is an emergency.
• Timely recognition of antibody deficiency prevents future
organ damage.
• If PID is suspected or runs in the family, delay live-
attenuated vaccinations and do not postpone immuno-
logical investigations.
• Use age-matched reference values to avoid misinterpreta-
tion of immunological test results.
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Table 1. Symptoms and signs that could point to potential PID.
(a) History
The hallmark of PID: infection history
Recurrent (probably) bacterial infections (more frequent than expected at the patient’s age)
More than one severe infection (e.g. meningitis, osteomyelitis, pneumonia, sepsis)
Infections that present atypically, are unusually severe or chronic or fail regular treatment (especially if i.v. antibiotics are needed)
Abscess of internal organ
Recurrent subcutaneous abscesses (especially in children)
Prolonged or recurrent diarrhoea
Any infection caused by an unexpected or opportunistic pathogen (e.g. pneumocystis)
Severe or long-lasting warts, generalized mollusca contagiosa
Extensive candidiasis, recurrent oral thrush in children >1 year
Complications of vaccination (disseminated BCG or varicella infection, paralytic polio, rotavirus infection)
Remember the family history!
PID in the family; familial occurrence of similar symptoms (affected males related by the female line, or another clear pattern of inheritance)
Unexplained early infant deaths, deaths due to infection
Consanguinity in the (grand) parents (known or suspected)
Autoimmune disease or haematological malignancy in several family members
Other* (could point to PID, but may not)
Aplasia or hypoplasia of thymus (X-ray)
Angioedema
Auto-immune disease (especially auto-immune cytopenias, SLE)
Bleeding tendency
Congenital cardiac anomalies (mainly conotruncal defects)
Chronic diarrhoea, malabsorption, pancreatic insufficiency
Delayed separation of umbilical cord ( >4 weeks)
Delayed shedding of primary teeth
Developmental delay (progressive)
Difficult-to-treat obstructive lung disease
Eczema, dermatitis (severe, atypical)
Failure to thrive (child) or wasting (adult)
Graft-versus-host reaction after blood transfusion, or mother-to-child (infant) engraftment
Granulomas
Haemolysis
Hypersensitivity to sunlight
Hypocalcaemic seizures
Inflammatory bowel disease (atypical)
Malignancy (mainly lymphoma)
Non-allergic oedema
Poor wound healing; scarring
Recurrent fever
Rib or other skeletal anomalies (X-ray)
Thymoma
Unexplained bronchiectasis, pneumatoceles, interstitial lung disease
Vasculitis
(b) Physical examination
Skin and
appendages
Abnormal hair or teeth. Eczema. Neonatal erythroderma. (Partial) albinism. Pale skin. Incontinentia pigmenti. Nail dystrophy.
Extensive warts or molluscae. Congenital alopecia. Vitiligo. Petechiae (early onset, chronic). Cold abscesses. Telangiectasia.
Absence of sweating
Oral cavity Gingivostomatitis (severe). Periodontitis. Aphthae (recurrent). Giant oral ulcers. Thrush. Dental crowding. Conical incisors.
Enamel hypoplasia. Persistent deciduous teeth
Eyes Retinal lesions. Telangiectasia
Lymphoid tissue Absence of lymph nodes and tonsils. Lymphadenopathy (excessive). Asplenia. Organomegaly (liver, spleen)
Neurological Ataxia. Microcephaly. Macrocephaly
Other Angioedema (without urticaria). Digital clubbing. Dysmorphism. Stunted growth or disproportional growth
(c) Baseline blood tests
Haematology Granulocytopenia, lymphocytopenia, or neutrophilia. Eosinophilia. Giant or absent granules in phagocytes. Howell-Jolly bodies
Thrombocytopenia. Small platelets
Anaemia (aplastic, haemolytic)
Chemistry Hypocalcaemia. Hypofibrinogenaemia. Hypertriglyceridaemia. Hyperferritinaemia. Low CRP and other inflammatory
parameters during infections
*In alphabetical order. BCG: bacille Calmette–Guérin; CRP: C-reactive protein; i.v.: intravenous; PID: primary immunodeficiency; SLE: systemic lupus
erythematosus.
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Table 2. Pattern recognition gives direction to the diagnostic process.
Clinical presentation Encountered pathogens Special features
Non-immunological
differential diagnosis Diagnostic protocol
1 Recurrent ENT and airway
infections (including
bronchiectasis)
Most patients do not have PID.
Even if they do, it is seldom
life-threatening in the short
term (but may cause organ
damage in the long term).
Exclude more frequent
non-immunological
problems first, except in case
of a positive family history
Perform immunological tests
in case of bronchiectasis, if
>1 pneumonia occurs, or
when ENT infections persist
abnormally long
Mainly extracellular bacteria
such as Haemophilus
influenzae, Streptococcus
pneumoniae, Moraxella
catharralis
Sometimes: Staphylococcus
aureus, Neisseria
meningitidis, group A
Streptococcus, Mycoplasma
pneumoniae, Ureaplasma
urealyticum, Campylobacter
jejuni, Helicobacter pylori
Diarrhoea due to Giardia
lamblia.
Bronchiectasis. Recurrent
bronchitis in a non-smoker.
Unexplained chronic cough.
Chronic sinusitis
(Enteroviral
meningoencephalitis is a
severe complication in
inadequately substituted
agammaglobulinaemia)
Frequent, children: normal
frequency of infection in
infants (day-care, passive
smoking), bronchial
hyperreactivity, allergy,
asthma, adenoidal
hypertrophy, iron deficiency
anaemia, gastro-oesophageal
reflux
Frequent, adults: COPD
Infrequent, children: cystic
fibrosis, inhaled foreign
body, congenital anomaly,
BPD; intestinal or renal
protein loss
Infrequent, adults: cystic
fibrosis; intestinal or renal
protein loss.
Rare, children and adults:
ciliary dyskinesia,
a1-anti-trypsin deficiency
Go to protocol 1
2 Failure to thrive from early
infancy (including
intractable diarrhoea, severe
eczema)
Only a few of these children
have PID, but delay in
diagnosis and treatment by
SCT greatly impairs survival.
Perform immunological tests
in parallel with tests for
other causes of failure to
thrive.
Mainly viruses (CMV, EBV,
VZV, HSV, adenovirus,
HHV8, HPV, molluscum
contagiosum, RSV), fungi
(superficial Candida,
Aspergillus, Cryptococcus,
Histoplasma, Pneumocystis
jiroveci/carinii), protozoa
(Toxoplasma,
Microsporidium,
Cryptosporidium) and
intracellular bacteria such as
Mycobacterium spp. and
Salmonella
Intractable diarrhoea with or
without identified pathogen
Unusual infections or unusually
severe course of infections,
opportunistic infections
Graft-versus-host reaction from
maternal T lymphocytes or
non-irradiated blood
transfusion
Severe eczema Photosensitivity
A variety of gastrointestinal,
renal, cardiopulmonary,
endocrine, neurological,
metabolic and congenital
causes. Malignancy. Chronic
lead poisoning. Perinatal
infection. Severe
malnutrition (see
appropriate textbooks)
Go to protocol 2
3 Recurrent pyogenic infections
(including granulomatous
inflammation, poor wound
healing)
Defects in phagocyte function
are rare and seldom
immediately life-threatening.
Neutropenia is more
common and easily detected
Mainly Staphylococcus aureus,
sometimes Klebsiella,
Escherichia coli, Enterobacter,
Serratia, Pseudomonas,
Salmonella, Chromobacterium
violaceum, Burkholderia
species. Invasive fungal
infection (disseminated
Candida, Aspergillus,
Nocardia)
Infections of body surface areas
(skin, mouth, mucous
membranes), abscesses of
internal organs (lung, liver,
lymph nodes, gut) and
bones. Unexplained
granulomatous
inflammation. Poor wound
healing. Aphthae.
Granulomatous colitis with
severe rectal involvement.
Delayed separation of
umbilical cord (>4 weeks)
Neutropenia due to drugs;
alloimmune, autoimmune;
haematological malignancy,
aplastic anaemia. Transient
neutropenia following (viral)
infections. Vitamin
B12/folate deficiency
Disrupted skin (eczema, burns)
Go to protocol 3
4 Unusual infections or unusually
severe course of infections
(unexplained – periodic
fever, see 6)
An uncommon presentation of
a common disease is more
common than an
uncommon disease (such as
immunodeficiency). Perform
immunological screening
tests at an early stage,
however, because underlying
immunodeficiency may be
life-threatening
Mainly intracellular bacteria
such as Mycobacterium spp.
and Salmonella, viruses
(CMV, EBV, VZV, HSV, JC,
HPV), fungi (Candida,
Aspergillus, Cryptococcus,
Histoplasma, Pneumocystis
jiroveci/carinii) and protozoa
(Toxoplasma,
Microsporidium,
Cryptosporidium).
May present later in life Early
onset; association of multiple
features; atypical resistance
to treatments; opportunistic
infections
Virulent strain of pathogen,
reduced general condition of
patient leading to secondary
immunodeficiency
(malignancy, malnutrition,
chronic disease).
Immunosuppressive therapy.
HIV
Go to protocol 2
5 Recurrent infections with the
same type of pathogen
Many have no PID, but the
recurrent infections may be
life-threatening. Screening is
therefore warranted
Intracellular bacteria such as
Salmonellae, mycobacteria
Neisseriae such as meningococci
Yeasts, fungi such as candida
Encapsulated bacteria such as
pneumococci
Viruses
Normally no other recurrent
infectious problems
No/delayed fever/raise in CRP:
deficiency in NF-kB
signalling (IRAK4,
NEMO-ID, IkBa deficiency).
Encapsulated bacterial sepsis:
asplenia
Excessive warts:
epidermodysplasia
verruciformis, WHIM,
DOCK8
Herpesviruses: NK-cell
deficiency. X-linked
lymphoproliferative
syndrome
Increased exposure,
coincidence. Inadequate
treatment of first infection.
Anatomical defect (e.g.
fistula). Colonization. Occult
infection acting as reservoir
(e.g. endocarditis, abscess).
Asplenia
Intracellular bacteria: go to
protocol 2 step 2b (T
lymphocyte–macrophage
interaction for cytokine
production; autoantibodies
to IFN-g)
Neisseriae: go to protocol 1
(complement deficiency,
sometimes antibody
deficiency)
Yeasts, fungi: go to protocol 2
(T lymphocyte deficiency,
CMC, MPO)
Encapsulated bacteria: go to
protocol 1 (antibody
deficiency, IRAK4 deficiency,
complement deficiencies)
Viruses: go to protocol 2
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Table 2. Continued
Clinical presentation Encountered pathogens Special features
Non-immunological
differential diagnosis Diagnostic protocol
6 Autoimmune or chronic
inflammatory disease;
lymphoproliferation
Most cases of autoimmune
disease, chronic
inflammatory disease, and
lymphoproliferation are not
associated with recurrent
infections. If the
combination occurs, or if the
case presents atypically or at
an unexpected age,
immunodeficiency is more
likely
When combinations of clinical
presentations are present,
look there. Generally
autoinflammatory disorders
do not present serious
infectious problems
Distinct combinations of
clinical conditions including
autoimmune diseases, acute
phase reactants,
lymphoproliferation. Identify
by clinical features. Atypical
HUS. Unexplained
haemolysis
(See appropriate textbooks.) Start with protocol 1, 2 or 3
guided by predominant
clinical presentation (1–5,
see above)
When in doubt perform a
combination of the tests in
steps 1 from all three
protocols
7 Characteristic combinations of
clinical features (eponymous
syndromes)
Many primarily
non-immunological
syndromes show features of
immunodeficiency. See
suggestive symptoms and
signs in Table 1
Different syndromes are
associated with particular
forms of immunodeficiency
and concomitant infectious
problems
Identify syndrome by clinical
features
(See appropriate textbooks for
non-immunological
syndrome characteristics. See
ref [26].)
Follow appropriate protocol
guided by predominant
clinical presentation
(1–6, see above). Perform
appropriate tests for the
particular syndrome.
When in doubt perform a
combination of the tests in
step 1 from all three
protocols
8 Angioedema – Related to triggering factors
(e.g. stress, trauma, menses)
Symptoms typically last
>24 h. Not reacting to
epinephrine/antihistamine/
corticosteroid treatment.
May mimic acute abdomen
Allergy, malignancy,
auto-immunity
ACE-inhibitor therapy
Idiopathic
Go to protocol 1 step 2b
Columns 1 and 5 are the core of the table, and can be used to go directly to the appropriate diagnostic protocol, guided solely by the clinical presentation of the patient. Columns 2
and 3 contain extra information that can be useful, but does not necessarily have to be used. Column 4 contains information on the non-immunological differential diagnosis. ACE,
angiotensin-converting enzyme; BPD, bronchopulmonary dysplasia; CMC, chronic mucocutaneous candidiasis; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disorder;
CRP, C-reactive protein; EBV, Epstein-Barr virus; ENT, ear-nose-throat; HHV8, human herpes virus 8; HIV, human immunodeficiency virus; HPV, human papilloma virus; HSV, herpes
simplex virus; HUS, haemolytic uraemic syndrome; IRAK4, interleukin-1 receptor-associated kinase 4; JC, JC virus; MPO, myeloperoxidase; NEMO-ID, X-linked mutations in nuclear
factor (NF)-kB essential modulator with immune deficiency and often ectodermal dysplasia with anhydrosis (EDA); NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells;
NK, natural killer; PID, primary immunodeficiency disease; RSV, respiratory syncytial virus; SCT, stem cell transplantation; VZV, varicella zoster virus,WHIM, warts, hypogammaglobu-
linemia, infections and myelokathexis syndrome.
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Protocol 1
Step 1 Rule out severe antibody deficiency and neutropenia
Perform Blood count and differential (check platelet volume, absolute lymphocyte, neutrophil 
and eosinophil counts). IgG, IgA, and IgM. IgE. 
Next step Neutropenia: go to protocol 3, step 2. Agammaglobulinaemia : go to step 4. 
Hypogammaglobulinaemia : go to step 2a. Other : go to step 2b
Step 2a Predominantly antibody deficiencies 
Hypogamma
globulinaemia
If not secondary to drugs, lymphoid malignancy, thymoma, immunoglobulin loss 
(urine, faeces), perform: booster responses (tetanus; unconjugated pneumococcal 
vaccine if >2–3 years of age; a rise in titre 3–4 weeks after vaccination appropriate
for age to above a defined level should be considered a positive response), 
consider : IgG-subclasses (when IgG>4g/l) and M-proteins
Next step Go to step 4.
Step 2b Predominantly antibody deficiencies or complement deficiencies 
Normal results 
step 1
When positive family history or problems persist, perform: booster responses, CH50
and AP50, consider: IgG-subclasses and M-proteins; MBL, asplenia
In case of angioedema: C1-inhibitor level, C4 during attack
Next step Normal results: Wait and see. Repeat total IgG, IgA, IgM, and IgG-subclasses after 
1–2 years (6 months if <1 year of age), and booster responses after 3–5 years. 
Consider step 3. Consider lymphocyte subpopulations (Table 4), consider protocol 
3
Abnormal results: go to step 4
Normal results 
steps 1 & 2
When symptoms or signs from Table 1 are present: consult an immunologist to 
determine a specific work-up. Other potential explanations for recurrent infections do 
not always automatically exclude PID
Step 4 Final diagnosis 
Step 3 Other potential PIDs
Abnormal 
results step 1
Agammaglobulinaemia: lymphocyte subpopulations (Table 4), consider lymphocyte 
proliferation tests (Table 4), B cell maturation analysis in bone marrow. Genetic 
determination of defect if possible
Abnormal 
results step 2
IgG-subclass deficiency, IgA deficiency, abnormal booster responses, and/or 
hypogammaglobulinaemia: lymphocyte subpopulations (Table 4), consider 
lymphocyte proliferation tests (Table 4), chromosomal analysis, α-fetoprotein. 
Genetic determination of defect if possible. If still undefined: consider step 3; 
consider protocol 3; repeat total IgG, IgA, IgM and IgG-subclasses after 1–2 years, 
and booster responses after 3–5 years
Abnormal CH50 and/or AP50 : determination of individual complement components 
(e.g. C1q,C2,C4,C5–C9, properdin, factor B/I/H). ANA
In case of angioedema: C1-inhibitor function (if level is normal). Genetic 
determination of defect if possible
Abnormal 
results step 3
Follow appropriate work-up guided by clinical presentation and laboratory results. 
Genetic determination of defect if possible
Fig. 1. Protocol 1. ANA: anti-nuclear antibody; C: complement; CD: cluster of differentiation; Ig: immunoglobulin; MBL: mannose binding lectin;
PID: primary immunodeficiency. Grey shading: consultation with an immunologist is highly recommended.
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Finland; M. Hönig, Department of Paediatrics, Unive-
rsity Hospital Ulm, Ulm, Germany; M. G. Kanariou, Spe-
cific Center & Referral Center for Primary Immunodefi-
ciencies – Paediatric Immunology, ‘Aghia Sophia’ Children’s
Hospital, Athens, Greece; M. Kirschfink, Institute of Immu-
nology, University of Heidelberg, Heidelberg, Germany;
C. Klein, University Children’s Hospital, Dr von Hauner-
sches Kinderspital, Munich, Germany; T.W. Kuijpers,
Division of Paediatric Hematology, Immunology and Infec-
tious diseases, Emma Children’s Hospital, Academic
Medical Center, Amsterdam, the Netherlands; N. Kutuk-
culer, Department of Pediatrics, Division of Pediatric
Immunology, Ege University, Izmir, Turkey; B. Mar-
tire, Dipartimento di Biomedicina dell’Eta′ Evolutiva,
Protocol 2
Step 1 Don’t hesitate to rule out SCID and AIDS 
Perform Blood count and differential (check platelet volume, absolute lymphocyte, neutrophil 
and eosinophil counts); IgG, IgA, and IgM; IgE; lymphocyte subpopulations (Table 
4); tests for HIV  
Next step HIV-positive: treat accordingly. Agammaglobulinaemia, lymphocytopenia : go to step 
2a. Normal results, but no improvement, no other diagnosis: go to step 2a. The 
possibility of SCID is an emergency! Early SCT can save lives  
Step 2a Combined T and B cell immunodeficiencies 
Perform Lymphocyte subpopulations and proliferation tests (Table 4). Consider lymphocyte 
subpopulations using a more extended protocol than the one mentioned in Table 4. 
Hypogammaglobulinaemia: consider secondary causes; add IgG-subclasses, 
booster responses, M-proteins  
Next step Abnormal results : go to step 4. Normal results : consider step 3, consider protocol 3.
Step 2b Identify T lymphocyte - macrophage communication defects 
Perform T lymphocyte/macrophage communication (IL-12, IL-12-receptor, IFN-γ -receptor, 
STAT1) by referral to specialist centre
Next step Normal results: go to step 1, if not yet performed. Consider step 3. Consider 
protocol 3. Abnormal results: Genetic determination of defect if possible  
Step 3 Other potential PIDs 
Normal results 
steps 1 & 2
When symptoms or signs from Table 1 are present: consult an immunologist to 
determine a specific work-up. Other potential explanations for recurrent infections do 
not always automatically exclude PID  
Step 4 Final diagnosis 
Clinical status Test for chimerism (maternal T lymphocytes). Analyse and treat possible infections 
(consider viral PCR/culture/serology, BAL, organ biopsy for histology and culture; 
look for opportunistic pathogens with appropriate techniques); serology is 
unreliable! 
Immune system Consider in vitro cytokine production, in vivo functional tests (e.g. stimulation with 
neoantigen; PPD or candida skin tests), analysis of bone marrow, lymph node 
biopsy. NK cell cytotoxicity  
Underlying 
defect
Consider uric acid, ADA, PNP, α-fetoprotein, X-ray of long bones if short stature or 
disproportional growth, thymus size (chest X-ray, ultrasound), chromosomal 
analysis, radiosensitivity tests, 22q11 analysis, clonality studies (Vβ-gene usage). 
Determination of genetic defect if possible  
Fig. 2. Protocol 2. ADA: adenosine deaminase; AIDS: acquired immunodeficiency syndrome; BAL: bronchoalveolar lavage; CD: cluster of
differentiation; HIV: human immunodeficiency virus; Ig: immunoglobulin; IFN: interferon; IL: interleukin; NK: natural killer; PID: primary
immunodeficiency; PNP: purine nucleoside phosphorylase; PPD: purified protein derivative; SCID: severe combined immunodeficiency; SCT: stem
cell transplantation; STAT: signal transducers and activators of transcription. Grey shading: consultation with an immunologist is highly
recommended.
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Policlinico Università di Bari, Bari, Italy; I. Meyts, Depart-
ment of Paediatrics, University Hospitals Leuven, Leuven,
Belgium; T. Niehues, Helios Klinikum Krefeld; Krefeld
Immunodeficiency Centre KIDZ, Krefeld, Germany; C.
Pignata, Department of Paediatrics, ‘Federico II’ University,
Naples, Italy; S. M. Reda, Department of Paediatric Allergy
and Immunology, Faculty of Medicine, Ain Shams Uni-
versity, Cairo, Egypt; E. D. Renner, University Children’s
Hospital, Ludwig Maximilians Universität, München,
Germany; N. Rezaei, Molecular Immunology Research
Centre and Research Group for Immunodeficiencies, Chil-
dren’s Medical Center, Tehran University of Medical
Sciences, Tehran, Iran; M. Rizzi, Center for Chronic Immu-
nodeficiency, University Medical Center Freiburg, Frei-
burg, Germany; M. A. Sampalo Lainz, Department
of Immunology, Puerta del Mar Universitary Hospital,
Cadiz, Spain; R. B. Sargur, Department of Immunology,
Northern General Hospital, Sheffield, UK; A. Sediva, Insti-
tute of Immunology, University Hospital Motol, Prague,
Czech Republic; M. G. Seidel, Paediatric Immunology
Outpatient Clinic, St Anna Children’s Hospital, Vienna,
Austria; S. L. Seneviratne, Department of Clinical Immu-
nology, St Mary’s Hospital and Imperial College, London,
UK; P. Soler-Palacín, Pediatric Infectious Diseases and
Immunodeficiencies Unit, Vall d’Hebron University Hospi-
tal, Barcelona, Spain; A. Tommasini, Laboratory of Immu-
nopathology, Institute for Maternal and Child Health,
IRCCS Burlo Garofolo, Trieste, Italy; K. Warnatz, Centre of
Protocol 3
Step 1 Identify neutropenia 
Perform Blood count and differential (absolute neutrophil count, microscopic evaluation; 
giant granules, bilobed nuclei, Howell-Jolly bodies); perform repeatedly in case of 
cyclic pattern of fever and infections (no evidence-based guidelines exist; 3 × /week 
for 3-6 weeks is advocated in several reviews)
Next step Neutropenia: go to step 2. Neutrophilia: go to step 3. Normal results: determine IgG, 
IgA, IgM, CH50; if normal, go to step 3; if abnormal go to protocol 1
Step 2 Identify the cause of the neutropenia 
Isolated 
neutropenia
Consider secondary causes: drug use, autoimmunity, alloimmunity (neonate), viral 
infection, agammaglobulinaemia. Perform: autoantibodies, alloantibodies (neonate), 
IgG, IgA, IgM; consider ANA, C3/C4, RF, ANCA, Coombs. If normal: analysis of 
bone marrow (morphology, cytogenetic studies). Consider associated 
immune/metabolic disorder and appropriate tests (exocrine pancreatic function, 
echocardiography, brain imaging, hearing test, skin and hair analysis) 
Go to step 4  
Pancytopenia Analysis of bone marrow (morphology, cytogenetic studies, immunophenotyping). 
Collaborate with a haematologist  
Step 3 Identify defects in phagocyte function 
Perform Normal neutrophil count: phagocyte function tests (Table 5). Serum IgE. Consider 
electron microscopy, hair evaluation. Neutrophilia: consider CD11b/CD18, sLeX, 
kindlin3 expression (flowcytometry)  
Next step Abnormal results: go to step 4. Normal results: go to protocol 1. Consider periodic 
fever syndromes; IgD, CRP, ESR, cytokines and urine mevalonic acid during attack; 
when abnormal go to step 4  
Step 4 Final diagnosis 
Perform Determine genetic defect if possible. 
Fig. 3. Protocol 3. ANA: anti-nuclear antibody; ANCA: anti-neutrophil cytoplasmic antibodies; C: complement component; CD: cluster of
differentiation; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GCSF: granulocyte–colony-stimulating factor; Ig: immunoglobulin;
RF: rheumatoid factor; sLeX: sialyl-Lewis X. Grey shading: consultation with an immunologist is highly recommended.
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Chronic Immunodeficiency, University Hospital of
Freiburg, Freiburg, Germany.
Disclosure
None.
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